MonoTotal ELISA has been CE marked in accordance with the European IVD Directive | IDL Biotech
IDL Biotech

CLOSE MENU

Articles

Lung cancer

June 2013

MonoTotal ELISA has been CE marked in accordance with the European IVD Directive

IDL Biotech tumor marker MonoTotal® ELISA has been registered by the Swedish Medical Product Agency for the use in the EU.

MonoTotal® is used for diagnosis, prognosis and therapy monitoring of lung cancer.

MonoTotal® has previously only been available as a radioactive immunoassay (MonoTotal® IRMA). The use of radioactive immunoassays is limited to very few countries. IDL Biotech has now developed an ELISA version of MonoTotal® with equal performance to the radioactive immunoassay; ELISA technology is a global standard method, thus providing many more countries an opportunity to use the product.

 

Lung cancer is one of the most common cancer forms with a high mortality rate. Early diagnose and good prognosis contributes to improved survival rates. Control after surgery and follow up after cancer treatment are also important factors in the management of patients. MonoTotal® is therefore an important complement to other clinical methods.

Annual meeting/Årsstämma

Årsstämma hålls den 27 maj 2020 kl. 15.00 på Piperska Muren, Scheelegatan 14, 112 28 Stockholm.

IDL Biotech signs new distribution agreement with Beckman Coulter, which gives the distributor global sales rights for the company's tumor markers on the ELISA manual platform.

Beckman Coulter has been one of IDL Biotech's most successful tumor markers distributors, and has sold the products in the Czech Republic and Slovakia for many years. With Beckman Coulter now taking over the global distribution rights for the company's tumor markers, we can intensify our focus on rapid testing and automation. At the same time, it gives Beckman Coulter the opportunity to broaden his product portfolio within tumor markers, ”says Charlotte Berg, CEO of IDL Biotech. IDL Biotech will continue to produce the tumor markers. The agreement is global, excluding the Chinese market.

IDL Biotech

Skip this intro